Maraviroc

The first of a new class of antiretroviral agents

Rodger David MacArthur, Richard M. Novak

Research output: Contribution to journalReview article

146 Citations (Scopus)

Abstract

Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalClinical Infectious Diseases
Volume47
Issue number2
DOIs
StatePublished - Jul 15 2008
Externally publishedYes

Fingerprint

Anti-Retroviral Agents
Pharmaceutical Preparations
HIV-1
Virus Attachment
Tropism
Chemokine Receptors
United States Food and Drug Administration
Licensure
Drug Interactions
Membrane Proteins
Pharmacokinetics
Pharmacology
Viruses
Safety
maraviroc
Proteins

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Maraviroc : The first of a new class of antiretroviral agents. / MacArthur, Rodger David; Novak, Richard M.

In: Clinical Infectious Diseases, Vol. 47, No. 2, 15.07.2008, p. 236-241.

Research output: Contribution to journalReview article

@article{6e0b955db9294a86b985217d29335f6e,
title = "Maraviroc: The first of a new class of antiretroviral agents",
abstract = "Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.",
author = "MacArthur, {Rodger David} and Novak, {Richard M.}",
year = "2008",
month = "7",
day = "15",
doi = "10.1086/589289",
language = "English (US)",
volume = "47",
pages = "236--241",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Maraviroc

T2 - The first of a new class of antiretroviral agents

AU - MacArthur, Rodger David

AU - Novak, Richard M.

PY - 2008/7/15

Y1 - 2008/7/15

N2 - Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.

AB - Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.

UR - http://www.scopus.com/inward/record.url?scp=46349097362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46349097362&partnerID=8YFLogxK

U2 - 10.1086/589289

DO - 10.1086/589289

M3 - Review article

VL - 47

SP - 236

EP - 241

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -